Nature Search

Dual Bcl-2/Bcl-xl inhibition via AZD0466 combines with immune checkpoint blockade to enhance anti-tumour activity

Dane M. Newman
Courtney L. Andersen
Ricky W. Johnstone
ResearchOpen Access06 Jan 2026
Cell Death & Disease

Volume: 17, P: 1-9
Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma

Katherine L DeYoung
Michael E Ray
Jeffrey M Trent
Research24 Jul 1997
Oncogene

Volume: 15, P: 453-457
Anticancer activities of histone deacetylase inhibitors

Johnstone and colleagues discuss the molecular events that underlie the anticancer effects of histone deacetylase inhibitors, and consider how the clinical development and application of these agents may be optimized, either as monotherapies or in combination with other anticancer drugs.

Jessica E. Bolden
Melissa J. Peart
Ricky W. Johnstone
Reviews01 Sept 2006
Nature Reviews Drug Discovery

Volume: 5, P: 769-784
A member of the Pyrin family, IFI16, is a novel BRCA1-associated protein involved in the p53-mediated apoptosis pathway

Jason A Aglipay
Sam W Lee
Toru Ouchi
Research04 Dec 2003
Oncogene

Volume: 22, P: 8931-8938
Role of IFI 16, a member of the interferon-inducible p200-protein family, in prostate epithelial cellular senescence

Hong Xin
Jonathan Curry
Divaker Choubey
Research31 Jul 2003
Oncogene

Volume: 22, P: 4831-4840
Erratum: A chemical probe toolbox for dissecting the cancer epigenome

Jake shortt
Christopher J. Ott
James E. Bradner
Amendments and Corrections23 Mar 2017
Nature Reviews Cancer

Volume: 17, P: 268
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

Katrina J. Falkenberg
Ricky W. Johnstone
Amendments and Corrections27 Feb 2015
Nature Reviews Drug Discovery

Volume: 14, P: 219
Manipulation of B-cell responses with histone deacetylase inhibitors

Histone deaceytelase inhibitors are used in the treatment of haematological malignancies but can also act as modulators of the immune system. Here, the authors show that histone deaceytelase inhibitors are capable of modulating B-cell functions leading to improved outcome in autoimmune conditions.

Michaela Waibel
Ailsa J. Christiansen
Edwin D. Hawkins
Research27 Apr 2015
Nature Communications

Volume: 6, P: 1-12
Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene

The Eμ-Myc lymphoma mouse model has been invaluable in the study of this disease. Here, the authors use multiple sequencing strategies to analyse the tumours in these mice and find recurrent inactivating mutations in Bcor, suggesting that this gene has a negative role in Mycsignalling.

Marcus Lefebure
Richard W. Tothill
Ricky W. Johnstone
ResearchOpen Access06 Mar 2017
Nature Communications

Volume: 8, P: 1-10
A_2AR eGFP reporter mouse enables elucidation of A_2AR expression dynamics during anti-tumor immune responses

Adenosine is an immunosuppressive metabolite known to limit anti-tumor immune responses. Here the authors report the characterization of an adenosine A2A receptor (A2AR) eGFP reporter mouse, providing immunological insights into the biology of A2AR expression in the context of anti-tumor immunity.

Kirsten L. Todd
Junyun Lai
Paul A. Beavis
ResearchOpen Access01 Nov 2023
Nature Communications

Volume: 14, P: 1-15
The TRAIL apoptotic pathway in cancer onset, progression and therapy

Tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors (TRAILR1 and TRAILR2) are promising targets for cancer therapy: both recombinant TRAIL and monoclonal antibodies that target these receptors have entered clinical trials. How are these agents faring? What are the current stumbling blocks?

Ricky W. Johnstone
Ailsa J. Frew
Mark J. Smyth
Reviews01 Oct 2008
Nature Reviews Cancer

Volume: 8, P: 782-798
Targeting transcription cycles in cancer

This Review discusses the concept of transcription cycles in cancer, providing a framework for our understanding of dysregulated transcription in cancer and therapeutic targeting of dysregulated transcription cycles.

Stephin J. Vervoort
Jennifer R. Devlin
Ricky W. Johnstone
Reviews21 Oct 2021
Nature Reviews Cancer

Volume: 22, P: 5-24
Targeting the epigenetic regulation of antitumour immunity

Aberrant epigenetic processes can influence tumour immunogenicity and immune cells involved in the response to cancer. This Review highlights how epigenetic regulators can be modulated with small-molecule drugs to promote antitumour immune responses, and discusses the opportunities and challenges for developing cancer treatment regimens that combine epigenetic therapies with immunotherapies.

Simon J. Hogg
Paul A. Beavis
Ricky W. Johnstone
Reviews14 Sept 2020
Nature Reviews Drug Discovery

Volume: 19, P: 776-800
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

Histone deacetylases (HDACs) are a class of epigenetic enzymes that remove acetyl groups from lysine residues on histones and other proteins. In this Review, the authors highlight the role of HDACs in cancer, neurological diseases and immune disorders, and discuss the development of small-molecule inhibitors.

Katrina J. Falkenberg
Ricky W. Johnstone
Reviews18 Aug 2014
Nature Reviews Drug Discovery

Volume: 13, P: 673-691
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

High expression of Mcl-1 promotes tumorigenesis and resistance to anticancer therapies. Here they report a macrocyclic molecule with high selectivity and affinity for Mcl-1 that exhibits potent anti-tumor effects as single agent and in combination with bortezomib or venetoclax in preclinical models of multiple myeloma and acute myeloid leukemia.

Adriana E. Tron
Matthew A. Belmonte
Alexander W. Hird
ResearchOpen Access17 Dec 2018
Nature Communications

Volume: 9, P: 1-14
Functional interaction between p53 and the interferon-inducible nucleoprotein IFI 16

Ricky W Johnstone
Wu Wei
Joseph A Trapani
Research07 Dec 2000
Oncogene

Volume: 19, P: 6033-6042
A chemical probe toolbox for dissecting the cancer epigenome

This review summarizes the state of the art in chemical probes targeting molecular processes operating at the chromatin interface in cancer cells. It seeks to provide a chemical toolbox for use by scientists to dissect epigenetic vulnerabilities of tumour biology.

Jake Shortt
Christopher J. Ott
James E. Bradner
Reviews23 Feb 2017
Nature Reviews Cancer

Volume: 17, P: 160-183
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

Ricky W. Johnstone
Reviews01 Apr 2002
Nature Reviews Drug Discovery

Volume: 1, P: 287-299
Antigen-driven EGR2 expression is required for exhausted CD8⁺ T cell stability and maintenance

Exhausted T cells arise when chronic activation triggers functional defects. Here the authors show that chronic antigenic stimulation in both tumour and infection models induces the expression of EGR2, which drives and stabilises exhausted cell epigenetic and transcriptional identity.

Mayura V. Wagle
Stephin J. Vervoort
Ian A. Parish
ResearchOpen Access13 May 2021
Nature Communications

Volume: 12, P: 1-15
Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis

BCL6 corepressor (BCOR) is recurrently mutated in acute myeloid leukaemia and myelodysplastic syndrome. Here, the authors use mouse models to show the mechanism of how inactivation of BCOR in haematopoietic stem cells contributes to the development of leukaemia.

Madison J. Kelly
Joan So
Lev M. Kats
ResearchOpen Access22 Mar 2019
Nature Communications

Volume: 10, P: 1-14
Functional interdependence of BRD4 and DOT1L in MLL leukemia

The histone methyltransferase DOT1L and the chromatin reader BRD4 together facilitate transcription of genes critical to the molecular pathogenesis of MLL leukemia.

Omer Gilan
Enid Y N Lam
Mark A Dawson
Research13 Jun 2016
Nature Structural & Molecular Biology

Volume: 23, P: 673-681
Joseph F. Sambrook (1939–2019)

Ashley Dunn
Ricky W. Johnstone
Bruce Stillman
Comments & Opinion23 Sept 2019
Nature Structural & Molecular Biology

Volume: 26, P: 846-847
Fas ligand–mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas

Immune surveillance has been proposed to eliminate transformed cells and thereby limit tumor formation. Axel Kallies and colleagues now report that spontaneous B cell lymphoma development in Blimp1-deficient or Bcl6-overexpressing mice is accelerated by T cell deficiency and identify the Fas-Fas ligand pathway as a crucial mediator of T cell control of lymphoma growth.

Shoukat Afshar-Sterle
Dimitra Zotos
Axel Kallies
Research02 Feb 2014
Nature Medicine

Volume: 20, P: 283-290
Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth

Selective inhibitors of KAT6A and KAT6B inhibit MYST-catalysed histone acetylation, induce cell cycle exit and cellular senescence without causing DNA damage, and arrest lymphoma progression in mouse models.

Jonathan B. Baell
David J. Leaver
Tim Thomas
Research01 Aug 2018
Nature

Volume: 560, P: 253-257
BET inhibitor resistance emerges from leukaemia stem cells

BET inhibitors that target bromodomain chromatin readers such as BRD4 are being explored as potential therapeutics in cancer; here, in a MLL–AF9 mouse leukaemia model, resistance to BET inhibitors is shown to emerge from leukaemia stem cells, and be partly due to increased Wnt/β-catenin signalling.

Chun Yew Fong
Omer Gilan
Mark A. Dawson
Research14 Sept 2015
Nature

Volume: 525, P: 538-542
A community-based model of rapid autopsy in end-stage cancer patients

Kathryn Alsop
Heather Thorne
David D Bowtell
Correspondence12 Sept 2016
Nature Biotechnology

Volume: 34, P: 1010-1014
T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments

Here, leukaemia cells are followed by intravital microscopy as they infiltrate mouse bone marrow and respond to chemotherapy, revealing that at all stages analysed they are highly motile and do not display any associations with particular bone marrow sub-compartments.

Edwin D. Hawkins
Delfim Duarte
Cristina Lo Celso
Research17 Oct 2016
Nature

Volume: 538, P: 518-522
Epigenetic control of mitochondrial cell death through PACS1-mediated regulation of BAX/BAK oligomerization

Daniella Brasacchio
Amber E Alsop
Joseph A Trapani
Research06 Jan 2017
Cell Death & Differentiation

Volume: 24, P: 961-970
Epigenetic modulators of B cell fate identified through coupled phenotype-transcriptome analysis

Isabella Y. Kong
Stephanie Trezise
Edwin D. Hawkins
ResearchOpen Access13 Jul 2022
Cell Death & Differentiation

Volume: 29, P: 2519-2530
Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia

Emily Gruber
Rheana L. Franich
Lev M. Kats
Research13 Jul 2020
Leukemia

Volume: 34, P: 3388-3392
Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs

Emma K Baker
Ricky W Johnstone
Assam El-Osta
Research08 Aug 2005
Oncogene

Volume: 24, P: 8061-8075
A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies

Darren C. Phillips
Sha Jin
Andrew J. Souers
ResearchOpen Access11 Dec 2019
Leukemia

Volume: 34, P: 1646-1657
A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity

K J Falkenberg
A Newbold
R W Johnstone
Research12 Feb 2016
Cell Death & Differentiation

Volume: 23, P: 1209-1218
Down-regulation of a pro-apoptotic pathway regulated by PCAF/ADA3 in early stage gastric cancer

Daniella Brasacchio
Rita A. Busuttil
Joseph A. Trapani
ResearchOpen Access18 Apr 2018
Cell Death & Disease

Volume: 9, P: 1-10
Induction of autophagy does not alter the anti-tumor effects of HDAC inhibitors

A Newbold
S J Vervoort
R W Johnstone
CorrespondenceOpen Access06 Sept 2012
Cell Death & Disease

Volume: 3, P: e387
A functional genomics screen identifies PCAF and ADA3 as regulators of human granzyme B-mediated apoptosis and Bid cleavage

D Brasacchio
T Noori
J A Trapani
Research24 Jan 2014
Cell Death & Differentiation

Volume: 21, P: 748-760
HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses

J E Bolden
W Shi
R W Johnstone
ResearchOpen Access28 Feb 2013
Cell Death & Disease

Volume: 4, P: e519
HDAC3 activity is required for initiation of leukemogenesis in acute promyelocytic leukemia

P Mehdipour
F Santoro
S Minucci
Correspondence24 Jan 2017
Leukemia

Volume: 31, P: 995-997
Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia

M Waibel
S J Vervoort
R W Johnstone
Correspondence15 Sept 2017
Leukemia

Volume: 32, P: 237-241
Histone deacetylase inhibitors are unable to synergize with ABT-737 in killing primary chronic lymphocytic leukaemia cells in vitro

R Ralli
K M Banks
A E Alsop
Correspondence06 Jan 2012
Leukemia

Volume: 26, P: 1433-1435
Genome-wide functional genomic and transcriptomic analyses for genes regulating sensitivity to vorinostat

Katrina J Falkenberg
Cathryn M Gould
Kaylene J Simpson
ResearchOpen Access08 Jul 2014
Scientific Data

Volume: 1, P: 1-13
The role of p21^waf1/cip1 and p27^Kip1 in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma

A Newbold
J M Salmon
R W Johnstone
Research02 Dec 2013
Oncogene

Volume: 33, P: 5415-5423
A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML

L M Kats
S J Vervoort
R W Johnstone
Correspondence10 Mar 2017
Leukemia

Volume: 31, P: 1466-1470
Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy

J Shortt
A K Hsu
R W Johnstone
Reviews14 Jan 2013
Oncogene

Volume: 32, P: 4191-4202

Search

Filter By:

Search

Quick links